VT
PTCT icon

Vise Technologies’s PTC Therapeutics PTCT Stock Holding History

Vise Technologies’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$748K Hold
9,842
– – 0.01% 690
2025
Q4 		$748K Buy
9,842
+756
+8% +$54.9K 0.01% 695
2025
Q3 		$558K Sell
9,086
-855
-9% -$44.5K 0.02% 627
2025
Q2 		$486K Buy
+9,941
New +$472K 0.02% 660
2024
Q4 		$461K Sell
10,215
-672
-6% -$28.8K 0.04% 462
2024
Q3 		$404K Sell
10,887
-3,429
-24% -$115K 0.05% 360
2024
Q2 		$438K Buy
14,316
+1,168
+9% +$37.8K 0.08% 248
2024
Q1 		$382K Buy
13,148
+340
+3% +$9.52K 0.08% 246
2023
Q4 		$353K Buy
12,808
+2,140
+20% +$48.9K 0.08% 239
2023
Q3 		$239K Buy
10,668
+1,673
+19% +$62.2K 0.06% 286
2023
Q2 		$366K Buy
8,995
+473
+6% +$23.1K 0.09% 220
2023
Q1 		$413K Buy
8,522
+444
+5% +$20.3K 0.11% 193
2022
Q4 		$308K Buy
8,078
+1,306
+19% +$54.3K 0.1% 230
2022
Q3 		$340K Buy
+6,772
New +$332K 0.13% 195

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vise Technologies's PTCT Position: Q1 2026 in Review

Vise Technologies held its PTC Therapeutics (PTCT) position steady in Q1 2026 at 9,842 shares worth $748K. The position accounts for 0.01% of the portfolio, ranked #690.

Vise Technologies first reported a position in PTCT in Q3 2022 and has held it in 14 quarters since. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Vise Technologies held 9,842 shares of PTC Therapeutics worth $748K as of Q1 2026.
  • Vise Technologies left its PTC Therapeutics share count unchanged in Q1 2026.
  • PTC Therapeutics made up 0.01% of Vise Technologies's portfolio in Q1 2026, its #690 holding.
  • Vise Technologies first reported a position in PTC Therapeutics in Q3 2022 and has held it in 14 quarters since.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Vise Technologies's 13F filing for Q1 2026, filed 21 Apr 2026.